batchsize=3;
event_count=5;
year=2013;
month=5;
day=24;
hour=0;
minute=26;
second=32;
event_date=2013-05-13 07:33:27;
sort_date=41407.314896;
event_date=2013-05-02 13:07:48;
sort_date=41396.547083;
event_date=2013-05-02 10:54:15;
sort_date=41396.454340;
Analyst Comment by
Deutsche BankDeutsche Bank reiterates buy rating on Sanofi SA
event_date=2013-05-02 03:16:46;
sort_date=41396.136644;

Chief Pulse Comment by Christopher A Viehbacher
PARIS French drugs giant Sanofi SA ( SNY) Thursday said it expects a return to growth later in the year as the effects of lost of patent protection on key drugs eases and new products come through its pipeline."The
Group expects to resume growth in the second half," Sanofi Chief Executive Chris Viehbacher said, presenting a sharp drop in company's first quarter earnings. Still, he noted double digit growth, percentage wise over the quarter from three businesses the company is banking on for future growth: diabetes, vaccines and the biotech company Genzyme. Mr. Viehbacher added that early launch trends for multiple sclerosis treatment Aubagio and emergency allergy treatment Auvi Q in the U. S are "encouraging."
Share:
PARIS French drugs giant Sanofi SA ( SNY) Thursday said it expects a return to growth later in the year as the effects of lost of patent protection on key drugs eases and new products come through its pipeline."The <span class="sent">Group expects to resume growth in the second half," Sanofi Chief Executive Chris Viehbacher said, presenting a sharp drop in company's first quarter earnings.</span> Still, he noted double digit growth, percentage wise over the quarter from three businesses the company is banking on for future growth: diabetes, vaccines and the biotech company Genzyme. Mr. Viehbacher added that early launch trends for multiple sclerosis treatment Aubagio and emergency allergy treatment Auvi Q in the U. S are "encouraging."
Tweet this
read full story
event_date=2013-04-25 11:29:42;
sort_date=41389.478958;

Chief Pulse Comment by Christopher Viehbacher
The new study, looking only at those patients, will start by the third quarter of 2013, Lilly said in December.
Sanofi Chief Executive Officer Chris Viehbacher said earlier this month the French drugmaker won't pursue an Alzheimer's treatment because the science isn't advanced enough to justify the cost. The first Alzheimer's drugs, if successful, would lead to a market worth $20 billion, Barbara Ryan, a former Deutsche Bank analyst estimated last year. .
Share:
The new study, looking only at those patients, will start by the third quarter of 2013, Lilly said in December. <span class="sent"><span class="company">Sanofi</span> Chief Executive Officer <span class="analyst">Chris Viehbacher</span> said earlier this month the French drugmaker won't pursue an Alzheimer's treatment because the science isn't advanced enough to justify the cost.</span> The first Alzheimer's drugs, if successful, would lead to a market worth $20 billion, Barbara Ryan, a former Deutsche Bank analyst estimated last year. .
Tweet this
read full story